Antiretroviral therapy among people with HIV with comorbidities in the United States: a retrospective cohort study

References

• Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349–e356.
   PubMed Web of Science ®Google Scholar
• Marcus JL, Leyden WA, Alexeeff SE, et al. Comparison of overall and Comorbidity-Free life expectancy between insured adults with and without HIV infection, 2000–2016. JAMA Netw Open. 2020;3(6):e207954. doi: 10.1001/jamanetworkopen.2020.7954.
   PubMed Web of Science ®Google Scholar
• Richterman A, Sax PE. Antiretroviral therapy in older people with HIV. Curr Opin HIV AIDS. 2020;15(2):118–125. doi: 10.1097/COH.0000000000000614.
   PubMed Web of Science ®Google Scholar
• Wada N, Jacobson LP, Cohen M, et al. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984–2008. Am J Epidemiol. 2013;177(2):116–125. doi: 10.1093/aje/kws321.
   PubMed Web of Science ®Google Scholar
• Bonnet F, Le Marec F, Leleux O, et al. Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort. BMC Infect Dis. 2020;20(1):850. doi: 10.1186/s12879-020-05593-4.
   PubMed Web of Science ®Google Scholar
• Pourcher V, Gourmelen J, Bureau I, et al. Comorbidities in people living with HIV: an epidemiologic and economic analysis using a claims database in France. PLOS One. 2020;15(12):e0243529. doi: 10.1371/journal.pone.0243529.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120–1126. doi: 10.1093/cid/cir627.
   PubMed Web of Science ®Google Scholar
• Nanditha NGA, Paiero A, Tafessu HM, et al. Excess burden of age-associated comorbidities among people living with HIV in British Columbia, Canada: a population-based cohort study. BMJ Open. 2021;11(1):e041734. doi: 10.1136/bmjopen-2020-041734.
   PubMed Web of Science ®Google Scholar
• Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59(12):1787–1797. doi: 10.1093/cid/ciu701.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2021 [cited 2022 June 22]. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines
   Google Scholar
• Healthy People. What’s new in the guidelines? Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2022. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new-guidelines
   Google Scholar
• European AIDS Clinical Society. Guidelines: version 9.1. 2018 [cited 2022 June 22]. Accessed at https://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf
   Google Scholar
• World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens. 2019. https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?ua=1
   Google Scholar
• Rodriguez-Penney AT, Iudicello JE, Riggs PK, et al. Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS. 2013;27(1):5–16. doi: 10.1089/apc.2012.0329.
   PubMed Web of Science ®Google Scholar
• Collins LF, Armstrong WS. What it means to age with HIV infection: years gained are not comorbidity free. JAMA Netw Open. 2020;3(6):e208023. doi: 10.1001/jamanetworkopen.2020.8023.
   PubMed Web of Science ®Google Scholar
• Paudel MP, Buysman EK, Goswami S, et al. Comorbidity and comedication burden among people living with HIV in the United States. Curr Med Res Opin. 2022;38(8):1443–1450.
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi: 10.1093/aje/kwq433.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. Chronic Conditions Data Warehouse (CCW). 2022 [2022 June 06]. https://www2.ccwdata.org/web/guest/condition-categories
   Google Scholar
• Do AN, Rosenberg ES, Sullivan PS, et al. Excess burden of depression among HIV-infected persons receiving medical care in the United States: data from the medical monitoring project and the behavioral risk factor surveillance system. PLOS One. 2014;9(3):e92842. doi: 10.1371/journal.pone.0092842.
   PubMed Web of Science ®Google Scholar
• Gallant J, Hsue PY, Shreay S, et al. Comorbidities among US patients with prevalent HIV Infection-A trend analysis. J Infect Dis. 2017;216(12):1525–1533.
   PubMed Web of Science ®Google Scholar
• Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J. 2014;35(21):1373–1381. doi: 10.1093/eurheartj/eht528.
   PubMed Web of Science ®Google Scholar
• Islam FM, Wu J, Jansson J, et al. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis. BMC Public Health. 2012;12(1):234. doi: 10.1186/1471-2458-12-234.
   PubMedGoogle Scholar
• Priest J, Bhak RH, Dersarkissian M, et al. Retrospective analysis of adherence to HIV treatment and healthcare utilization in a commercially insured population. J Med Econ. 2021;24(1):1204–1211. doi: 10.1080/13696998.2021.1995868.
   PubMed Web of Science ®Google Scholar
• Bakal DR, Coelho LE, Luz PM, et al. Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors. J Antimicrob Chemother. 2018;73(8):2177–2185. doi: 10.1093/jac/dky145.
   PubMed Web of Science ®Google Scholar
• Brown TT, Hoy J, Borderi M, et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis. 2015;60(8):1242–1251. doi: 10.1093/cid/civ010.
   PubMed Web of Science ®Google Scholar
• Brown TT, Moser C, Currier JS, et al. Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. J Infect Dis. 2020;221(12):2083–2084. doi: 10.1093/infdis/jiv194.
   PubMed Web of Science ®Google Scholar
• Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–2174. doi: 10.1097/QAD.0b013e32801022eb.
   PubMed Web of Science ®Google Scholar
• Chawla A, Wang C, Patton C, et al. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infect Dis Ther. 2018;7(2):183–195. doi: 10.1007/s40121-018-0201-6.
   PubMed Web of Science ®Google Scholar
• Patel N, Abdelsayed S, Veve M, et al. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Ann Pharmacother. 2011;45(3):317–324. doi: 10.1345/aph.1P576.
   PubMed Web of Science ®Google Scholar
• Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D: A: D international prospective multicohort study. Lancet HIV. 2018;5(6):e291–e300. doi: 10.1016/S2352-3018(18)30043-2.
   PubMed Web of Science ®Google Scholar
• De Clercq J, Rutsaert S, De Scheerder MA, et al. Benefits of antiretroviral therapy initiation during acute HIV infection. Acta Clin Belg. 2022;77(1):168–176. doi: 10.1080/17843286.2020.1770413.
   PubMed Web of Science ®Google Scholar
• Margolis AM, Heverling H, Pham PA, et al. A review of the toxicity of HIV medications. J Med Toxicol. 2014;10(1):26–39. doi: 10.1007/s13181-013-0325-8.
   PubMedGoogle Scholar
• Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496–505. doi: 10.1086/655681.
   PubMed Web of Science ®Google Scholar
• Kalayjian RC, Lau B, Mechekano RN, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS. 2012;26(15):1907–1915. doi: 10.1097/QAD.0b013e328357f5ed.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: aids clinical trials group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791–1801. doi: 10.1093/infdis/jir188.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Thompson M, Sax PE, et al. Brief report: randomized, Double-Blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results. J Acquir Immune Defic Syndr. 2017;75(2):211–218. doi: 10.1097/QAI.0000000000001350.
   PubMed Web of Science ®Google Scholar
• Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–815. doi: 10.1056/NEJMoa1902824.
   PubMed Web of Science ®Google Scholar
• Van Buren PN, Toto R. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis. 2011;18(1):28–41. doi: 10.1053/j.ackd.2010.10.003.
   PubMed Web of Science ®Google Scholar
• Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143–155. doi: 10.1016/S0140-6736(18)32462-0.
   PubMed Web of Science ®Google Scholar
• Cahn P, Madero JS, Arribas JR, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-Week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020;83(3):310–318. doi: 10.1097/QAI.0000000000002275.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Brites C, Cheng C-Y, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2023;76(4):720–729. doi: 10.1093/cid/ciz1243.
   PubMed Web of Science ®Google Scholar
• Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867–875. doi: 10.1097/QAD.0b013e328351f68f.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Haas B, Segal-Maurer S, et al. Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment. AIDS Res Hum Retroviruses. 2018;34(4):337–342. doi: 10.1089/AID.2017.0203.
   PubMed Web of Science ®Google Scholar
• Raffi F, Orkin C, Clarke A, et al. Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. J Acquir Immune Defic Syndr. 2017;75(2):226–231. doi: 10.1097/QAI.0000000000001344.
   PubMed Web of Science ®Google Scholar
• Mukonzo JK, Okwera A, Nakasujja N, et al. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis. 2013;13(1):261. doi: 10.1186/1471-2334-13-261.
   PubMedGoogle Scholar
• Nkuize M, De Wit S, Muls V, et al. Upper gastrointestinal endoscopic findings in the era of highly active antiretroviral therapy. HIV Med. 2010;11(6):412–417.
   PubMed Web of Science ®Google Scholar
• Sherman DS, Fish DN. Management of protease inhibitor-associated diarrhea. Clin Infect Dis. 2000;30(6):908–914. doi: 10.1086/313826.
   PubMed Web of Science ®Google Scholar
• Castro E, Mateo J, Olmos D, et al. Targeting DNA repair: the role of PARP inhibition in the treatment of castration-resistant prostate cancer. Cancer J. 2016;22(5):353–356. doi: 10.1097/PPO.0000000000000219.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone N, Roediger MP, Eberly L, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLOS One. 2010;5(4):e10106. doi: 10.1371/journal.pone.0010106.
   PubMed Web of Science ®Google Scholar
• Obry-Roguet V, Bregigeon S, Cano CE, et al. Risk factors associated with overweight and obesity in HIV-infected people: aging, behavioral factors but not cART in a cross-sectional study. Medicine. 2018;97(23):e10956. doi: 10.1097/MD.0000000000010956.
   PubMed Web of Science ®Google Scholar
• Menard A, Meddeb L, Tissot-Dupont H, et al. Dolutegravir and weight gain: an unexpected bothering side effect? AIDS. 2017;31(10):1499–1500. doi: 10.1097/QAD.0000000000001495.
   PubMed Web of Science ®Google Scholar
• Norwood J, Turner M, Bofill C, et al. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527–531. doi: 10.1097/QAI.0000000000001525.
   PubMed Web of Science ®Google Scholar
• Bhagwat P, Ofotokun I, McComsey GA, et al. Changes in waist circumference in HIV-Infected individuals initiating a raltegravir or protease inhibitor regimen: effects of sex and race. Open Forum Infect Dis. 2018;5(11):ofy201. doi: 10.1093/ofid/ofy201.
   PubMed Web of Science ®Google Scholar
• Cuzin L, Pugliese P, Katlama C, et al. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort. J Antimicrob Chemother. 2019;74(3):754–760. doi: 10.1093/jac/dky497.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56–63. doi: 10.1111/hiv.12468.
   PubMed Web of Science ®Google Scholar
• Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. Curr Opin HIV AIDS. 2020;15(2):126–133. doi: 10.1097/COH.0000000000000608.
   PubMed Web of Science ®Google Scholar
• Greene M, Steinman MA, McNicholl IR, et al. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J Am Geriatr Soc. 2014;62(3):447–453. doi: 10.1111/jgs.12695.
   PubMed Web of Science ®Google Scholar